LY2886721

LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM) . LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment[1].

Product Specifications

CAS Number

[1262036-50-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Beta-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/LY2886721.html

Purity

99.72

Solubility

DMSO : ≥ 16.67 mg/mL

Smiles

FC1=CN=C(C=C1)C(NC2=CC=C(C([C@@]34[C@]([H])(CSC(N)=N4)COC3)=C2)F)=O

Molecular Formula

C18H16F2N4O2S

Molecular Weight

390.41

Precautions

H302, H315, H319, H335

References & Citations

[1]May PC1, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35 (3) :1199-210.